{"id":16763,"date":"2024-12-04T21:35:39","date_gmt":"2024-12-04T13:35:39","guid":{"rendered":"https:\/\/flcube.com\/?p=16763"},"modified":"2024-12-04T21:35:42","modified_gmt":"2024-12-04T13:35:42","slug":"keros-therapeutics-and-takeda-enter-licensing-agreement-for-elritercept-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=16763","title":{"rendered":"Keros Therapeutics and Takeda Enter Licensing Agreement for Elritercept Development"},"content":{"rendered":"\n

US-based Keros Therapeutics, Inc. (NASDAQ: KROS<\/a>) has announced a significant licensing agreement with Japan-headquartered Takeda (TYO: 4502<\/a>) to strengthen the research and development of its late-stage investigational activin inhibitor, elritercept.<\/p>\n\n\n\n

Elritercept’s Clinical Studies and Indications<\/strong>
Elritercept is currently the subject of two clinical studies, one focusing on myelodysplastic syndromes (MDS) and the other on myelofibrosis (MF). These conditions represent significant areas of unmet medical need, and elritercept has shown promise in addressing them.<\/p>\n\n\n\n

Terms of the Licensing Agreement<\/strong>
Under the terms of this agreement, Takeda will obtain development, manufacturing, and commercialization rights to elritercept worldwide, excluding mainland China, Hong Kong, and Macau. These territories are covered by a separate USD 190 million deal between China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692<\/a>) and Keros. As part of the agreement with Takeda, Keros will receive an upfront payment of USD 200 million. Additionally, Takeda is committed to making regulatory, development, and commercial sales milestone payments, as well as paying royalties on net sales of elritercept.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

US-based Keros Therapeutics, Inc. (NASDAQ: KROS) has announced a significant licensing agreement with Japan-headquartered Takeda…<\/p>\n","protected":false},"author":1,"featured_media":16765,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[363,1182,2614,2615,345,1141],"class_list":["post-16763","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-hansoh-pharmaceutical","tag-hkg-3692","tag-keros-therapeutics","tag-nasdaq-kros","tag-takeda","tag-tyo-4502"],"yoast_head":"\nKeros Therapeutics and Takeda Enter Licensing Agreement for Elritercept Development - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based Keros Therapeutics, Inc. (NASDAQ: KROS) has announced a significant licensing agreement with Japan-headquartered Takeda (TYO: 4502) to strengthen the research and development of its late-stage investigational activin inhibitor, elritercept.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=16763\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Keros Therapeutics and Takeda Enter Licensing Agreement for Elritercept Development\" \/>\n<meta property=\"og:description\" content=\"US-based Keros Therapeutics, Inc. (NASDAQ: KROS) has announced a significant licensing agreement with Japan-headquartered Takeda (TYO: 4502) to strengthen the research and development of its late-stage investigational activin inhibitor, elritercept.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=16763\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-04T13:35:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-04T13:35:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0466-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"602\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16763#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16763\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Keros Therapeutics and Takeda Enter Licensing Agreement for Elritercept Development\",\"datePublished\":\"2024-12-04T13:35:39+00:00\",\"dateModified\":\"2024-12-04T13:35:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16763\"},\"wordCount\":175,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16763#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0466-1.png\",\"keywords\":[\"Hansoh Pharmaceutical\",\"HKG: 3692\",\"Keros Therapeutics\",\"NASDAQ: KROS\",\"Takeda\",\"TYO: 4502\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=16763#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16763\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=16763\",\"name\":\"Keros Therapeutics and Takeda Enter Licensing Agreement for Elritercept Development - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16763#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16763#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0466-1.png\",\"datePublished\":\"2024-12-04T13:35:39+00:00\",\"dateModified\":\"2024-12-04T13:35:42+00:00\",\"description\":\"US-based Keros Therapeutics, Inc. (NASDAQ: KROS) has announced a significant licensing agreement with Japan-headquartered Takeda (TYO: 4502) to strengthen the research and development of its late-stage investigational activin inhibitor, elritercept.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16763#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=16763\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16763#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0466-1.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0466-1.png\",\"width\":1080,\"height\":602,\"caption\":\"Keros Therapeutics and Takeda Enter Licensing Agreement for Elritercept Development\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16763#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Keros Therapeutics and Takeda Enter Licensing Agreement for Elritercept Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Keros Therapeutics and Takeda Enter Licensing Agreement for Elritercept Development - Insight, China's Pharmaceutical Industry","description":"US-based Keros Therapeutics, Inc. (NASDAQ: KROS) has announced a significant licensing agreement with Japan-headquartered Takeda (TYO: 4502) to strengthen the research and development of its late-stage investigational activin inhibitor, elritercept.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=16763","og_locale":"en_US","og_type":"article","og_title":"Keros Therapeutics and Takeda Enter Licensing Agreement for Elritercept Development","og_description":"US-based Keros Therapeutics, Inc. (NASDAQ: KROS) has announced a significant licensing agreement with Japan-headquartered Takeda (TYO: 4502) to strengthen the research and development of its late-stage investigational activin inhibitor, elritercept.","og_url":"https:\/\/flcube.com\/?p=16763","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-12-04T13:35:39+00:00","article_modified_time":"2024-12-04T13:35:42+00:00","og_image":[{"width":1080,"height":602,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0466-1.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=16763#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=16763"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Keros Therapeutics and Takeda Enter Licensing Agreement for Elritercept Development","datePublished":"2024-12-04T13:35:39+00:00","dateModified":"2024-12-04T13:35:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=16763"},"wordCount":175,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=16763#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0466-1.png","keywords":["Hansoh Pharmaceutical","HKG: 3692","Keros Therapeutics","NASDAQ: KROS","Takeda","TYO: 4502"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=16763#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=16763","url":"https:\/\/flcube.com\/?p=16763","name":"Keros Therapeutics and Takeda Enter Licensing Agreement for Elritercept Development - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=16763#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=16763#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0466-1.png","datePublished":"2024-12-04T13:35:39+00:00","dateModified":"2024-12-04T13:35:42+00:00","description":"US-based Keros Therapeutics, Inc. (NASDAQ: KROS) has announced a significant licensing agreement with Japan-headquartered Takeda (TYO: 4502) to strengthen the research and development of its late-stage investigational activin inhibitor, elritercept.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=16763#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=16763"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=16763#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0466-1.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0466-1.png","width":1080,"height":602,"caption":"Keros Therapeutics and Takeda Enter Licensing Agreement for Elritercept Development"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=16763#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Keros Therapeutics and Takeda Enter Licensing Agreement for Elritercept Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0466-1.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16763","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16763"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16763\/revisions"}],"predecessor-version":[{"id":16766,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16763\/revisions\/16766"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/16765"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16763"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=16763"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=16763"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}